380 related articles for article (PubMed ID: 11309296)
21. Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment.
Berthiaume JM; Wallace KB
Cardiovasc Toxicol; 2007; 7(3):178-91. PubMed ID: 17901561
[TBL] [Abstract][Full Text] [Related]
22. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
23. Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicity.
Jing L; Wu Y; Wu J; Zhao J; Zuo D; Peng S
Eur J Pharmacol; 2011 Jun; 659(2-3):224-32. PubMed ID: 21463615
[TBL] [Abstract][Full Text] [Related]
24. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates.
Konorev EA; Kennedy MC; Kalyanaraman B
Arch Biochem Biophys; 1999 Aug; 368(2):421-8. PubMed ID: 10441396
[TBL] [Abstract][Full Text] [Related]
25. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
26. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets.
Sardão VA; Oliveira PJ; Holy J; Oliveira CR; Wallace KB
Cell Biol Toxicol; 2009 Jun; 25(3):227-43. PubMed ID: 18386138
[TBL] [Abstract][Full Text] [Related]
27. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
[TBL] [Abstract][Full Text] [Related]
28. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats.
Zordoky BN; Anwar-Mohamed A; Aboutabl ME; El-Kadi AO
Toxicol Appl Pharmacol; 2010 Jan; 242(1):38-46. PubMed ID: 19796650
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
Bruynzeel AM; Vormer-Bonne S; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2007 Sep; 60(4):509-14. PubMed ID: 17177067
[TBL] [Abstract][Full Text] [Related]
30. Metallothionein acts as a cytoprotectant against doxorubicin toxicity.
Kimura T; Fujita I; Itoh N; Muto N; Nakanishi T; Takahashi K; Azuma J; Tanaka K
J Pharmacol Exp Ther; 2000 Jan; 292(1):299-302. PubMed ID: 10604962
[TBL] [Abstract][Full Text] [Related]
31. Cardiomyocyte resistance to doxorubicin mediated by A(3) adenosine receptor.
Shneyvays V; Mamedova LK; Korkus A; Shainberg A
J Mol Cell Cardiol; 2002 May; 34(5):493-507. PubMed ID: 12056854
[TBL] [Abstract][Full Text] [Related]
32. Protective role of grape seed extract against doxorubicin-induced cardiotoxicity and genotoxicity in albino mice.
Yalçin E; Oruç E; Cavuşoğlu K; Yapar K
J Med Food; 2010 Aug; 13(4):917-25. PubMed ID: 20553142
[TBL] [Abstract][Full Text] [Related]
33. Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment.
Bottone AE; Voest EE; de Beer EL
Clin Cancer Res; 1998 Apr; 4(4):1031-7. PubMed ID: 9563899
[TBL] [Abstract][Full Text] [Related]
34. Antioxidant defense against anthracycline cardiotoxicity by metallothionein.
Kang YJ
Cardiovasc Toxicol; 2007; 7(2):95-100. PubMed ID: 17652812
[TBL] [Abstract][Full Text] [Related]
35. General oxidative stress during doxorubicin-induced cardiotoxicity in rats: absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid.
Ghibu S; Delemasure S; Richard C; Guilland JC; Martin L; Gambert S; Rochette L; Vergely C
Biochimie; 2012 Apr; 94(4):932-9. PubMed ID: 21396425
[TBL] [Abstract][Full Text] [Related]
36. Protective effects of an aged garlic extract on doxorubicin-induced cardiotoxicity in the mouse.
Kojima R; Toyama Y; Ohnishi ST
Nutr Cancer; 1994; 22(2):163-73. PubMed ID: 14502845
[TBL] [Abstract][Full Text] [Related]
37. Immunocytochemical localization of metallothionein and its relation to doxorubicin toxicity in transgenic mouse heart.
Zhou Z; Kang YJ
Am J Pathol; 2000 May; 156(5):1653-62. PubMed ID: 10793076
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of arabic gum against cardiotoxicity induced by doxorubicin in mice: a possible mechanism of protection.
Abd-Allah AR; Al-Majed AA; Mostafa AM; Al-Shabanah OA; Din AG; Nagi MN
J Biochem Mol Toxicol; 2002; 16(5):254-9. PubMed ID: 12439867
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity.
Kang YJ; Chen Y; Yu A; Voss-McCowan M; Epstein PN
J Clin Invest; 1997 Sep; 100(6):1501-6. PubMed ID: 9294117
[TBL] [Abstract][Full Text] [Related]
40. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration.
Gabizon A; Meshorer A; Barenholz Y
J Natl Cancer Inst; 1986 Aug; 77(2):459-69. PubMed ID: 3461207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
